Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AKBA – Akebia Therapeutics Inc.

Akebia Therapeutics, Inc.
AKBA
$1.61
Name : Akebia Therapeutics, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $427,239,264.00
EPSttm : -0.08
finviz dynamic chart for AKBA
Akebia Therapeutics, Inc.
$1.61
1.26%
$0.02

Float Short %

13.47

Margin Of Safety %

15

Put/Call OI Ratio

0.13

EPS Next Q Diff

EPS Last/This Y

0.37

EPS This/Next Y

0.13

Price

1.61

Target Price

5.4

Analyst Recom

1

Performance Q

-39.93

Relative Volume

0.55

Beta

0.35

Ticker: AKBA




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-02AKBA1.4750.140.4746058
2025-12-03AKBA1.570.140.1546669
2025-12-04AKBA1.5950.140.2546833
2025-12-05AKBA1.5350.140.1746894
2025-12-08AKBA1.6150.140.0447007
2025-12-09AKBA1.5850.140.0447133
2025-12-10AKBA1.6250.140.1447198
2025-12-11AKBA1.6650.140.1247299
2025-12-12AKBA1.6650.140.0047385
2025-12-15AKBA1.6150.140.0047729
2025-12-16AKBA1.6250.149.0047874
2025-12-17AKBA1.6150.130.0047812
2025-12-18AKBA1.670.130.1547815
2025-12-19AKBA1.6650.130.0047825
2025-12-22AKBA1.650.130.0045520
2025-12-23AKBA1.660.130.0945712
2025-12-26AKBA1.6550.130.0246587
2025-12-29AKBA1.6250.130.3546812
2025-12-30AKBA1.5850.132.0647289
2025-12-31AKBA1.6050.130.0447210
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-02AKBA1.47115.0- 0.04
2025-12-03AKBA1.57115.0- 0.04
2025-12-04AKBA1.60115.0- 0.04
2025-12-05AKBA1.54115.0- 0.04
2025-12-08AKBA1.62115.0- 0.04
2025-12-09AKBA1.58115.0- 0.04
2025-12-10AKBA1.58115.0- 0.04
2025-12-11AKBA1.66115.0- 0.04
2025-12-12AKBA1.66115.0- 0.04
2025-12-15AKBA1.61115.0- 0.04
2025-12-16AKBA1.61115.0- 0.04
2025-12-17AKBA1.61115.0- 0.04
2025-12-18AKBA1.67115.0- 0.04
2025-12-19AKBA1.66115.0- 0.04
2025-12-22AKBA1.67115.0- 0.04
2025-12-23AKBA1.65115.0- 0.04
2025-12-26AKBA1.65115.0- 0.04
2025-12-29AKBA1.62115.0- 0.04
2025-12-30AKBA1.58115.0- 0.04
2025-12-31AKBA1.61115.0- 0.04
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-02AKBA-0.806.6413.77
2025-12-03AKBA-0.806.6413.77
2025-12-04AKBA-0.806.6413.77
2025-12-05AKBA-0.806.6413.77
2025-12-08AKBA-0.656.7813.77
2025-12-09AKBA-0.656.7813.77
2025-12-10AKBA-0.656.7813.99
2025-12-11AKBA-0.656.7813.99
2025-12-12AKBA-0.486.7813.99
2025-12-15AKBA-0.486.7913.99
2025-12-16AKBA-0.486.7913.99
2025-12-17AKBA-0.486.7913.99
2025-12-18AKBA-0.486.7913.99
2025-12-19AKBA-0.486.7913.99
2025-12-22AKBA-0.486.7913.99
2025-12-23AKBA-0.486.7913.99
2025-12-26AKBA-0.486.7913.47
2025-12-29AKBA-0.486.8013.47
2025-12-30AKBA-0.486.8013.47
2025-12-31AKBA-0.486.8013.47
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.01

Avg. EPS Est. Next Quarter

0.01

Insider Transactions

-0.48

Institutional Transactions

6.8

Beta

0.35

Average Sales Estimate Current Quarter

56

Average Sales Estimate Next Quarter

59

Fair Value

1.84

Quality Score

70

Growth Score

52

Sentiment Score

34

Actual DrawDown %

68.8

Max Drawdown 5-Year %

-95.1

Target Price

5.4

P/E

Forward P/E

13.2

PEG

P/S

1.9

P/B

10.27

P/Free Cash Flow

13.28

EPS

-0.08

Average EPS Est. Cur. Y​

0.04

EPS Next Y. (Est.)

0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.07

Relative Volume

0.55

Return on Equity vs Sector %

-65.5

Return on Equity vs Industry %

-45.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

Akebia Therapeutics, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 181
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading